Feb 16, 2020 - Feb 20, 2020 / NTS GMT
Leonard Mazur - Citius Pharmaceuticals, Inc. - Director & Chairman of the Board
-- the fact that you're able to come to our meeting, I have realize you had multiple choices here and hopefully you'll find this to be worthwhile.
First of all, we have the usual disclaimer statement, but I do strongly encourage everybody to consult our website as well as sec.gov for any and all information on the company. We are in Nasdaq and so we are a fully reporting company.
In terms of the company itself, we have some great opportunities. We are different from other pharma companies in effect in a sense that there's some unique aspects to us.
First of all, we have late-stage assets. Our lead asset is a Phase 3 drug. We have a large market opportunity with -- where there are unmet needs and will be, upon approval, the only products in the marketplace. So that makes us, separates us from the rest of the pack.
We do have, as I always like to say, we have an expert team, but what separates us from everybody else is the fact that our team has put in its own money into the
Citius Pharmaceuticals Inc at Noble Capital Markets Small and Microcap Investor Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers